Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update
Editas Medicine, a leading genome editing company, announced a conference call and webcast on November 5, 2020, at 5:00 PM ET to discuss its third-quarter results and corporate updates.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Editas Medicine, a leading genome editing company, announced a conference call and webcast on November 5, 2020, at 5:00 PM ET to discuss its third-quarter results and corporate updates. Investors can access the call by dialing (844) 348-3801 domestically or (213) 358-0955 internationally. The conference ID is 9992536. A live webcast will be available on the Editas Medicine website.
Editas focuses on developing transformative genomic medicines using CRISPR technology.
Details
News Market Reaction – EDIT
The recorded move for EDIT in the trading session of this news was -5.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, November 5, 2020, at 5:00 p.m. ET to discuss a corporate update and results for the third quarter of 2020.
| Conference Call & Webcast Details | |
| Date: | Thursday, November 5, 2020 |
| Time: | 5:00 pm Eastern Time |
| Toll Free: | (844) 348-3801 |
| International: | (213) 358-0955 |
| Conference ID: | 9992536 |
| Webcast: | https://edge.media-server.com/mmc/p/b5td2coz |
A live webcast of the conference call can be accessed in the Investors section of Editas Medicine website at https://www.editasmedicine.com/.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts:
Investors
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.